Nkarta
NKTX
Market cap $150M

2.11 USD

-0.09

4.09%

At close Apr 25, 4:00 PM EDT

After hours

2.11

+0.00

0.00%

1 day

-4.09%

5 days

18.54%

1 month

47.55%

3 months

-12.81%

6 months

-36.64%

Year to date

-15.60%

1 year

-69.06%

5 years

-95.59%

10 years

-95.59%

About: Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Employees: 157

Healthcare Biotechnology

0

Funds holding %

of 7,419 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

142% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 19

6% less funds holding

Funds holding: 119 [Q3] → 112 (-7) [Q4]

6.52% less ownership

Funds ownership: 94.61% [Q3] → 88.09% (-6.52%) [Q4]

21% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 29

49% less capital invested

Capital invested by funds: $302M [Q3] → $155M (-$147M) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

99% less call options, than puts

Call options by funds: $68K | Put options by funds: $6.72M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

421%

upside

Avg. target

$14.33

579%

upside

High target

$18

753%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Needham Gil Blum 17% 1-year accuracy 27 / 157 met price target	421%upside $11	Buy Reiterated	9 Apr 2025
Stifel Stephen Willey 25% 1-year accuracy 5 / 20 met price target	564%upside $14	Buy Maintained	27 Mar 2025
HC Wainwright & Co. Emily Bodnar 18% 1-year accuracy 29 / 161 met price target	753%upside $18	Buy Reiterated	27 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about NKTX published over the past 30 days

Zacks Investment Research

Nkarta (NKTX) Upgraded to Buy: Here's Why

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nkarta (NKTX) Upgraded to Buy: Here's Why

Nkarta to Participate in an April Investor Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

Nkarta to Participate in an April Investor Conference

Nkarta: Grinding Lower, Trying To Find Support

Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with sufficient cash reserves to support ongoing research and development activities. Strengths include cutting-edge technology and strategic partnerships, while risks involve clinical trial uncertainties and regulatory hurdles.

Nkarta: Grinding Lower, Trying To Find Support

Nkarta: Betting On The Turnaround

Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract investor attention.

Nkarta: Betting On The Turnaround

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Nkarta, Inc. NKTX reported a fourth-quarter earnings report on Wednesday with a loss of 35 cents per share, beating the consensus of a loss of 41 cents.

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024.

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Zacks Investment Research

Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Nkarta (NKTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research

Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Nkarta (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Nkarta to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences:

Nkarta to Participate in March Investor Conferences

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

See News Rankings

Charts implemented using Lightweight Charts™